Quest Diagnostics (DGX) agreed to acquire select assets of Fresenius Medical Care's (FMS) Spectra Laboratories unit, which provides renal-specific laboratory testing services in the US, the companies said Monday.

Under a separate deal, Quest will provide laboratory services related to end-stage kidney disease and specialized water testing for patients and providers served by dialysis centers that Fresenius and its wholly owned and joint-venture partners operate in the US, according to a joint statement.

Financial terms weren't disclosed.

The acquisition is expected to close in H2, while the transition of services is anticipated to be completed by early 2026, the companies added.

Shares of Quest were up more than 4% and Fresenius was 0.7% higher in recent premarket activity.